启动别嘌醇治疗痛风时秋水仙碱预防相关不良事件的预后因素:回顾性队列研究
该回顾性队列研究利用英国临床实践研究数据链与医院统计数据库,纳入1997年4月1日至2016年11月30日启动别嘌醇并接受秋水仙碱预防的痛风成人患者13945例,描述秋水仙碱预防相关不良事件的潜在预后因素。结果显示26%(95% CI 25%,27%)的患者被处方一种或多种可能相互作用的药物,最常见为他汀类(21%,95% CI 20%,22%);他汀类与不良事件增加无关,但其他药物与部分不良结局相关;腹泻和心肌梗死与更多合并症及更严重慢性肾脏病相关。
要点
- 13945例启动别嘌醇的痛风患者中,26%(95% CI 25%,27%)被处方一种或多种可能相互作用的药物,最常见为他汀类(21%,95% CI 20%,22%)。
- 他汀类与不良事件增加无关,但其他药物与部分不良结局相关。
- 腹泻和心肌梗死与更多合并症及更严重慢性肾脏病相关。
核心结论
- 患者在接受秋水仙碱预防时,常已有可能与秋水仙碱相互作用的药物处方。
- 合并症更多及使用某些可能相互作用药物的患者中不良事件更常见。
- 研究结果可为止痛风启动别嘌醇时关于预防的治疗决策提供秋水仙碱相关不良事件预后因素的信息。
研究设计与样本
- 回顾性队列研究,使用英国临床实践研究数据链与医院统计数据库关联数据集。
- 纳入1997年4月1日至2016年11月30日启动别嘌醇并接受秋水仙碱预防的痛风成人患者13945例,平均年龄63.9岁(标准差14.7),男性占78.2%。
主要发现
- 26%(95% CI 25%,27%)的患者被处方一种或多种可能相互作用的药物,最常见为他汀类(21%,95% CI 20%,22%)。
- 他汀类与不良事件增加无关,但其他药物与部分不良结局相关。
- 腹泻和心肌梗死与更多合并症及更严重慢性肾脏病相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Colchicine is commonly used to prevent flares when starting urate-lowering therapy for gout. Patients with gout are frequently concurrently prescribed other medications (such as statins) that may interact with colchicine, increasing the risk of adverse events. The aim of this study was to describe potential prognostic factors for adverse events in patients prescribed colchicine when initiating allopurinol. METHODS: We conducted a retrospective cohort study in linked UK Clinical Practice Research Datalink and Hospital Episode Statistics datasets. Adults initiating allopurinol for gout with colchicine (1 April 1997 to 30 November 2016) were included. Potential prognostic factors were defined, and the likelihood of adverse events, including diarrhoea, nausea or vomiting, myocardial infarction, neuropathy, myalgia, myopathy, rhabdomyolysis and bone marrow suppression, were estimated. RESULTS: From 1 April 1997 to 30 November 2016, 13 945 people with gout initiated allopurinol with colchicine prophylaxis [mean age 63.9 (s.d. 14.7) years, 78.2% male]. One-quarter (26%, 95% CI 25%, 27%) were prescribed one or more potentially interacting medicines, most commonly statins (21%, 95% CI 20%, 22%). Statins were not associated with increased adverse events, although other drugs were associated with some adverse outcomes. Diarrhoea and myocardial infarction were associated with more comorbidities and more severe chronic kidney disease. CONCLUSION: People were given colchicine prophylaxis despite commonly having preexisting prescriptions for medications with potential to interact with colchicine. Adverse events were more common in people who had more comorbidities and certain potentially interacting medications. Our findings will provide much-needed information about prognostic factors for colchicine-related adverse events that can inform treatment decisions about prophylaxis when initiating allopurinol.
引用
- Bajpai R, Partington R, Muller S, et al. Prognostic factors for colchicine prophylaxis-related adverse events when initiating allopurinol for gout: retrospective cohort study. Rheumatology (Oxford). 2025. PMID: 38636489. doi:10.1093/rheumatology/keae229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。